This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaFocus: Vaccine Adjuvants In Infectious Disease

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global vaccine adjuvant market in future.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 10

2.1 Catalyst 10

3 Vaccines and the Host Immune Response 11

3.1 Vaccines in Infectious Disease 11

3.2 Host Immune Response 12

3.2.1 Primary Barriers Against Infection 12

3.2.2 Innate Immune System 13

3.2.3 Adaptive Immune System 15

3.3 Vaccine Adjuvants 18

3.3.1 Overview 18

3.3.2 Adjuvant Target: Dendritic Cells 19

3.3.3 Adjuvant Target: Toll-Like Receptors 22

3.3.4 Splenic Involvement in Immune Response 25

3.3.5 Antigen-Depot Effect 25

4 Market Drivers and Barriers 27

4.1 Overview 27

4.2 Drivers 28

4.2.1 Driver: Government initiatives to increase vaccination programs 28

4.2.2 Driver: New routes of administration for vaccines 29

4.2.3 Driver: Rapidly mutating pathogens 29

4.2.4 Driver: Recombinant vaccine technology 30

4.2.5 Driver: Increased research efforts against unvaccinated disease 30

4.3 Barriers 31

4.3.1 Barrier: Decreasing or stagnant vaccination rates 31

4.3.2 Barrier: Increasing vaccine prices 32

4.3.3 Barrier: Public opinion of vaccine and adjuvants 33

5 Current Adjuvant Options 34

5.1 Overview 34

5.2 Product Profiles – Major Adjuvant Classes 37

5.2.1 Aluminum Salts (Alum) 37

5.2.2 Emulsions 40

5.2.3 Particulate Delivery Mechanisms 43

5.2.4 Microbial Derivatives 46

5.2.5 Oligonucleotides 49

5.2.6 Adjuvant Systems 52

6 Needs Assessment and Opportunity Analysis 56

6.1 Overview 56

6.2 Unmet Needs Analysis 57

6.2.1 Adjuvant Safety 57

6.2.2 DC Recognition 57

6.2.3 Appropriate TLR Activation 58

6.2.4 Formulation and Dosing 58

6.3 Opportunity Analysis 60

6.3.1 Novel Routes of Administration and Splenic Involvement 60

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs